Boulder GX

Boulder GX was paid $120K by Medicaid between May 2022 and May 2024, across 27 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 45% of everything it billed.

33Billing provider infoBOULDER GX
SPRING, TX 77386

33aNPI1447911409assigned 01/03/2022

33bProvider typeClinical Medical Laboratory

28Total paid$120K

24GClaims9,624

24DCodes billed27

24AFirst – last monthMay 2022 – May 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#138 of 436

Median peer was paid$17K

This provider vs. median7.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	4,553	$89K
2023	4,541	$21K
2024incomplete	530	$10K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	45%	892	753	$54K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	15%	171	152	$18K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	15%	851	753	$18K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	10%	1,082	681	$12K
87631		6.1%	197	189	$7K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	2.0%	355	279	$2K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	1.2%	1,969	1,940	$1K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.1%	183	135	$1K
87481		<1%	104	68	$641.20
87590		<1%	142	100	$621.08
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	180	116	$605.05
86696		<1%	127	88	$487.62

15 more codes

87625		<1%	130	$398.18
86780		<1%	127	$364.77
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	451	$332.60
87563		<1%	17	$327.55
87500		<1%	70	$309.07
86695		<1%	128	$298.73
87808		<1%	137	$278.23
87640		<1%	508	$232.51
87486		<1%	610	$196.44
87641		<1%	57	$177.07
87541		<1%	592	$164.86
87581		<1%	483	$63.10
87086	Culture, bacterial; quantitative colony count, urine	<1%	14	$17.21
87653		0%	12	$0.00
87632		0%	35	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialZACK, SCOTT (OWNER)

Same official

Other billing entities under ZACK, SCOTT

Full network →

Provider	Location	Paid
Total Lab Solutions LLC	Troy, MI	$768K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.